FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

Zhang, Wu; Gordon, Michael; Schultheis, Anne M; Yang, Dong Yun; Nagashima, Fumio; Azuma, Mizutomo; Chang, Heung-Moon; Borucka, Eva; Lurje, Georg; Sherrod, Andy E; Iqbal, Syma; Groshen, Susan; Lenz, Heinz-Josef

Zhang, Wu; Gordon, Michael; Schultheis, Anne M; Yang, Dong Yun; Nagashima, Fumio; Azuma, Mizutomo; Chang, Heung-Moon; Borucka, Eva; Lurje, Georg; Sherrod, Andy E; Iqbal, Syma; Groshen, Susan; Lenz, Heinz-Josef.

Affiliation

Zhang W; Division of Medical Oncology, Department of Pathology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA.

J Clin Oncol ; 25(24): 3712-8, 2007 Aug 20.

Article in En | MEDLINE | ID: mdl-17704420

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Colorectal Neoplasms/drug therapy; Polymorphism, Genetic; Receptors, IgG/genetics; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents/adverse effects; Cetuximab; Colorectal Neoplasms/genetics; Colorectal Neoplasms/mortality; Colorectal Neoplasms/pathology; Disease-Free Survival; ErbB Receptors/metabolism; Female; Genotype; Humans; Male; Middle Aged; Survival Rate

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Polymorphism, Genetic / Colorectal Neoplasms / Receptors, IgG / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 2007 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links